| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 93.086 | 172.113 | 163.987 | 41.579 | - | - |
| Total Income - EUR | - | - | - | - | 93.096 | 172.510 | 163.996 | 41.579 | - | - |
| Total Expenses - EUR | - | - | - | - | 69.908 | 156.043 | 152.446 | 43.893 | - | - |
| Gross Profit/Loss - EUR | - | - | - | - | 23.188 | 16.466 | 11.550 | -2.314 | - | - |
| Net Profit/Loss - EUR | - | - | - | - | 20.664 | 14.911 | 10.107 | -2.709 | - | - |
| Employees | - | - | - | - | 2 | 1 | 2 | 1 | - | - |
Check the financial reports for the company - A&A Pharmaceutical And Nutrition Engineering Group
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 90 | 0 | 0 | - | - |
| Current Assets | - | - | - | - | 46.559 | 42.215 | 29.790 | 9.257 | - | - |
| Inventories | - | - | - | - | 30.995 | 25.794 | 16.833 | 3.379 | - | - |
| Receivables | - | - | - | - | 3.930 | 503 | 5.558 | 2.608 | - | - |
| Cash | - | - | - | - | 11.633 | 15.918 | 7.400 | 3.269 | - | - |
| Shareholders Funds | - | - | - | - | 20.748 | 24.801 | 26.079 | 7.525 | - | - |
| Social Capital | - | - | - | - | 84 | 496 | 485 | 487 | - | - |
| Debts | - | - | - | - | 25.810 | 17.504 | 3.711 | 1.731 | - | - |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4791 - 4791" | |||||||||
| CAEN Financial Year |
4791
|
|||||||||
Comments - A&A Pharmaceutical And Nutrition Engineering Group S.r.l.